These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 20345485)
1. Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin. Suzuki K; Kokuryo T; Senga T; Yokoyama Y; Nagino M; Hamaguchi M Cancer Sci; 2010 May; 101(5):1163-9. PubMed ID: 20345485 [TBL] [Abstract][Full Text] [Related]
2. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells. Lee J; Gollahon L Int J Oncol; 2013 Mar; 42(3):839-47. PubMed ID: 23340795 [TBL] [Abstract][Full Text] [Related]
3. Nek2 siRNA therapy using a portal venous port-catheter system for liver metastasis in pancreatic cancer. Kokuryo T; Hibino S; Suzuki K; Watanabe K; Yokoyama Y; Nagino M; Senga T; Hamaguchi M Cancer Sci; 2016 Sep; 107(9):1315-20. PubMed ID: 27316377 [TBL] [Abstract][Full Text] [Related]
4. Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma. Kokuryo T; Senga T; Yokoyama Y; Nagino M; Nimura Y; Hamaguchi M Cancer Res; 2007 Oct; 67(20):9637-42. PubMed ID: 17942892 [TBL] [Abstract][Full Text] [Related]
5. Nek2 as a novel molecular target for the treatment of breast carcinoma. Tsunoda N; Kokuryo T; Oda K; Senga T; Yokoyama Y; Nagino M; Nimura Y; Hamaguchi M Cancer Sci; 2009 Jan; 100(1):111-6. PubMed ID: 19038001 [TBL] [Abstract][Full Text] [Related]
6. Up-regulation of NEK2 by microRNA-128 methylation is associated with poor prognosis in colorectal cancer. Takahashi Y; Iwaya T; Sawada G; Kurashige J; Matsumura T; Uchi R; Ueo H; Takano Y; Eguchi H; Sudo T; Sugimachi K; Yamamoto H; Doki Y; Mori M; Mimori K Ann Surg Oncol; 2014 Jan; 21(1):205-12. PubMed ID: 24046120 [TBL] [Abstract][Full Text] [Related]
7. The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo. Jung HS; Erkin OC; Kwon MJ; Kim SH; Jung JI; Oh YK; Her SW; Ju W; Choi YL; Song SY; Kim JK; Kim YD; Shim GY; Shin YK Int J Cancer; 2012 Apr; 130(8):1925-36. PubMed ID: 21630254 [TBL] [Abstract][Full Text] [Related]
8. Mitotic perturbations induced by Nek2 overexpression require interaction with TRF1 in breast cancer cells. Lee J; Gollahon L Cell Cycle; 2013 Dec; 12(23):3599-614. PubMed ID: 24091727 [TBL] [Abstract][Full Text] [Related]
9. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. Ito M; Yamamoto S; Nimura K; Hiraoka K; Tamai K; Kaneda Y J Gene Med; 2005 Aug; 7(8):1044-52. PubMed ID: 15756713 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer. Zeng YR; Han ZD; Wang C; Cai C; Huang YQ; Luo HW; Liu ZZ; Zhuo YJ; Dai QS; Zhao HB; Liang YX; Zhong WD BMC Urol; 2015 Aug; 15():90. PubMed ID: 26320076 [TBL] [Abstract][Full Text] [Related]
11. Identification by high-throughput screening of viridin analogs as biochemical and cell-based inhibitors of the cell cycle-regulated nek2 kinase. Hayward DG; Newbatt Y; Pickard L; Byrne E; Mao G; Burns S; Sahota NK; Workman P; Collins I; Aherne W; Fry AM J Biomol Screen; 2010 Sep; 15(8):918-927. PubMed ID: 20664067 [TBL] [Abstract][Full Text] [Related]
12. The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells. Rivera-Rivera Y; Marina M; Jusino S; Lee M; Velázquez JV; Chardón-Colón C; Vargas G; Padmanabhan J; Chellappan SP; Saavedra HI Sci Rep; 2021 Apr; 11(1):9016. PubMed ID: 33907253 [TBL] [Abstract][Full Text] [Related]
13. Hepatoma cell functions modulated by NEK2 are associated with liver cancer progression. Wu SM; Lin SL; Lee KY; Chuang HC; Feng PH; Cheng WL; Liao CJ; Chi HC; Lin YH; Tsai CY; Chen WJ; Yeh CT; Lin KH Int J Cancer; 2017 Apr; 140(7):1581-1596. PubMed ID: 27925179 [TBL] [Abstract][Full Text] [Related]
14. Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin. Shi Y; Felley-Bosco E; Marti TM; Orlowski K; Pruschy M; Stahel RA BMC Cancer; 2012 Dec; 12():571. PubMed ID: 23211021 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of centrosome separation after DNA damage: a role for Nek2. Fletcher L; Cerniglia GJ; Nigg EA; Yend TJ; Muschel RJ Radiat Res; 2004 Aug; 162(2):128-35. PubMed ID: 15387139 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of Nek2 by small molecules affects proteasome activity. Meng L; Carpenter K; Mollard A; Vankayalapati H; Warner SL; Sharma S; Tricot G; Zhan F; Bearss DJ Biomed Res Int; 2014; 2014():273180. PubMed ID: 25313354 [TBL] [Abstract][Full Text] [Related]
17. FBXW7 circular RNA regulates proliferation, migration and invasion of colorectal carcinoma through NEK2, mTOR, and PTEN signaling pathways in vitro and in vivo. Lu H; Yao B; Wen X; Jia B BMC Cancer; 2019 Sep; 19(1):918. PubMed ID: 31519156 [TBL] [Abstract][Full Text] [Related]
18. Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells. Cappello P; Blaser H; Gorrini C; Lin DC; Elia AJ; Wakeham A; Haider S; Boutros PC; Mason JM; Miller NA; Youngson B; Done SJ; Mak TW Oncogene; 2014 May; 33(18):2375-84. PubMed ID: 23708664 [TBL] [Abstract][Full Text] [Related]
19. Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer. Mattheolabakis G; Ling D; Ahmad G; Amiji M Pharm Res; 2016 Dec; 33(12):2943-2953. PubMed ID: 27528390 [TBL] [Abstract][Full Text] [Related]
20. Role of NIMA-related kinase 2 in lung cancer: Mechanisms and therapeutic prospects. Shah D; Joshi M; Patel BM Fundam Clin Pharmacol; 2022 Oct; 36(5):766-776. PubMed ID: 35338518 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]